The Board of Directors of Fine Foods & Pharmaceuticals N.T.M. S.p.A today approved
the Group's Interim Financial Report as of 31 March 2024.
EBITDA Margin reached 13.5%, exceeding historical levels
Double-digit growth (+11.5%) in EBITDA in Q1 2024, evidence of an increasingly reliable organisation management.
- Revenue in Q1 2024 was € 65.6 million- stable compared to the extraordinary revenue recorded in Q1 2023, and this stability comes after two quarters of unprecedented high revenue.
- Q1 2024 EBITDA was € 8.9 million, up 11.5% compared to € 7.9 million in Q1 2023.
- Q1 2024 EBITDA Margin of 13.5%, improved from 12.1% in Q1 2023.
- Q1 2024 Operating Result (EBIT) was € 5.1 million compared to € 4.2 million in Q1 2023 (+20,7%).
- Profit for the period in Q1 2024 was € 2.8 million compared to € 2.9 million in Q1 2023.
- The Group's Net Financial Position as of 31 March 2024 was € 43.6 million, stable compared to 31
December 2023.
***
Verdellino (Bergamo, Italy), 15 May 2024 - The Board of Directors of Fine Foods & Pharmaceuticals N.T.M. S.p.A. - an Italian independent Contract Development & Manufacturing Organisation (CDMO) that develops and manufactures contract products for the pharmaceutical, nutraceutical, and cosmetics industries, listed on Euronext STAR Milan (ticker: FF), today approved the Group's Interim Financial Report as of 31 March 2024, prepared under IAS/IFRS Accounting Standards issued by the IASB (International Accounting Standards Board) and not subject to audit.
Q1 2024 reported Consolidated Revenue of € 65.6 million, in line with Q1 2023, which saw an exceptional revenue increase.
The Pharmaceuticals Business Unit recorded revenue of € 17.6 million in Q1 2024, +4.9% compared to the same period of 2023 (€ 16.8 million).
Nutraceuticals Business Unit revenue in Q1 2024 was € 39.8 million compared to € 40.7 million in the previous period with a slight decrease of 2.1%.
The contribution of the Cosmetic Business Unit in Q1 2024 was € 8.1 million, an increase of 0.3% compared to the same quarter of the previous year, showing the first signs of recovery after the integration and reorganisation process.
Fine Foods & Pharmaceuticals N.T.M. S.p.A. CEO Giorgio Ferraris said: "The first quarter 2024 showed revenue in line with 2023, with double-digitEBITDA growth and increasing margins that highlighted a reliable organisational management. Despite the international economic and geopolitical situation, we expect for 2024 a revenue growth trend in line with historical levels and overall margin improvement."
Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 info@finefoods.it
CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02
FINEFOODS.IT
EBITDA in Q1 2024 was € 8.9 million, +11.5% compared to € 7.9 million in Q1 2023. There was a decrease in the Raw Material costs to Sales Revenue ratio to approximately 58.6% compared to 60.1% as of 31 March 2023, and a progressive improvement in the organisational efficiency.
EBITDA Margin in Q1 2024 was 13.5% compared to 12.1% in Q1 2023. The improvement in margins was mainly due to a decrease in purchasing raw materials, packaging, and energy costs on revenue.
The Group's Operating result (EBIT) for the period benefited from what above, and was € 5.1 million, with an increase of € 0.9 million compared to 31 March 2023 (+21%).
Group Income Before Taxes in Q1 2024 was € 4 million, compared to € 4.3 million in Q1 2023. This figure was negatively impacted by the absence of the positive effects generated by the asset management.
Q1 2024 closed with a profit for the period of € 2.8 million, stable compared to Q1 2023 result of € 2.9 million.
Tangible Fixed Assets increased by approximately € 1.8 million in Q1 2024, due to net investments of approximately € 5.3 million and depreciation for the period of € 3.5 million.
Intangible fixed assets and rights of use were €16.3 million as of 31 March 2024, in line with the previous year-end. Other non-current receivables and payables decreased by about € 0.8 million.
Working capital as of 31 March 2024 was € 44.3 million compared to € 42.6 million at the end of the previous financial year. The Commercial Net Working Capital of € 50.7 million (€ 48.1 million as of 31 December 2023) saw an increase in trade receivables (€ 5.8 million) and trade payables (€ 0.8 million), and a decrease in inventories (€ 2.5 million). Other current receivables and payables decreased by approximately € 0.8 million.
Shareholders' Equity as of 31 March 2024 was € 129.6 million, (€ 126.9 million as of 31 December 2023).
The Group's Net Financial Position as of 31 March 2024 of € 43.6 million was stable compared to 31 December 2023 and showed a positive cash flow from operating activities of about € 5.6 million, net CAPEX made in the period of about € 5.5 million and purchase of treasury shares of about € 0.1 million.
SIGNIFICANT EVENTS OCCURRING AFTER 31 March 2024
No significant events occurred after the end of the period.
BUSINESS OUTLOOK
Despite the current international economic and geopolitical situation, and temporary shifts in some customers' inventory management, the target markets continue to expand. The Group is set on growing its market share and will persist in developing its business across three key sectors: Nutraceuticals, Pharmaceuticals, and Cosmetics by strengthening their operations. Fine Foods will seize any opportunities for growth through external lines.
The Nutra BU commercial strategies implemented, which focus on product quality, innovation, and enhancing customer support services, were confirmed. Fine Foods confirms the production capacity increase by expanding the current plant, which will bring favourable results on the top line in the 2024-2028five-year period. Initial investments are expected to start in the second half of the year.
In 2024, the Pharma BU will continue its preparatory activities for the strong growth expected buoyed by significant multi-year agreements signed with key international customers. Fine Foods confirms that work for the production plant expansion started at the end of 2023, and will be completed in 2025. The new site will start generating revenue from 2026.
The Cosmetic BU's organisation, integration, process optimisation and investments made due to increased efficiency and enhanced capacity to fulfil customer demands are showing positive signs. We expect a shift in trends leading to an increase in the top line and profit margins, contributing positively to the Group's results.
Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 info@finefoods.it
CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02
FINEFOODS.IT
The management is confident that the Group's revenue growth and margin improvement historical trends will continue in the upcoming quarters. Along with its financial objectives, the Group intends to continue its sustainability programme in this and future financial years, and serve as a benchmark for customers by assessing products that align with the evolving market demands, which include sustainability.
***
Under Art. 154-bis, paragraph 2 of the Consolidated Law on Financial Intermediation (TUF), the Manager responsible for preparing the corporate financial reports, Pietro Bassani, declared that the accounting information contained in this press release corresponds to the document results, accounting books and records. This press release is available on the website www.finefoods.it, in the Investor Relations/Press Releases section. The Interim Financial Report as of 31 March 2024 is available today from the 1Info authorised storage system (www.1Info.it), on website www.finefoods.it (Investor relations/Financial Reports section) and at the Company's registered office. The presentation of the 31 March 2024 results, approved today by the Board of Directors, is available at www.finefoods.it (Investor relations/Presentations section).
Attachments:
- Consolidated income statement
- Consolidated comprehensive income statement
- Consolidated statement of financial position
- Consolidated cash flow statement
- Consolidated Shareholders' equity changes
***
Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Borsa Italiana's Euronext STAR Milan (Ticker: FF) is an Italian independent CDMO (Contract Development and Manufacturing Organisation) It develops and manufactures contract products for the pharmaceutical, nutraceutical and cosmetics industries. Founded in 1984, Fine Foods proved to be a reliable and capable strategic partner for customers in the reference sectors. The company's organisation can provide successful design process and solid, long- term partnerships. The continuous search for excellence is part of the company's business model and includes research and development, innovation, process reliability, product quality, ESG, and sustainable management of the Group's supply chain. Fine Foods is a benefit corporation which relies on certifications and ratings under international standards. These guarantee its sustainability commitment across the business. With €251.8 million revenue in 2023, Fine Foods is a growing and future-oriented company.
For further information:
Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Tel +39 035 4821382
Investor Relations: ir@finefoods.it
Media Relations: media.relations@finefoods.it
Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 info@finefoods.it
CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02
FINEFOODS.IT
Consolidated income statement
(amounts in € units) | 3 months | 3 months | |||||
31 March 2024 | 31 March 2023 | ||||||
Revenue and income | 65,564,696 | 65,560,388 | |||||
Revenue from contracts with customers | |||||||
264,086 | |||||||
Other revenue and income | 228,337 | ||||||
Total revenue | 65,828,782 | 65,788,725 | |||||
Operating costs | |||||||
Costs for consumption of raw materials, change in inventories of finished goods | 38,426,273 | 39,416,667 | |||||
and work in progress. | 11,634,821 | 11,161,688 | |||||
Personnel costs | |||||||
Costs for services | 6,337,369 | 6,781,231 | |||||
Other operating costs | 565,724 | 480,458 | |||||
Amortisation, depreciation, and impairment losses | 3,796,105 | 3,748,501 | |||||
Total operating costs | 60,760,292 | 61,588,546 | |||||
Operating result | 5,068,490 | 4,200,180 | |||||
Changes in fair value of financial assets and liabilities | (19,496) | 1,101,887 | |||||
Financial income | 8,336 | 20,086 | |||||
Financial charges | (1,083,042) | (1,054,022) | |||||
Income before taxes | 3,974,288 | 4,268,131 | |||||
Income taxes | 1,156,496 | 1,361,792 | |||||
Profit/(loss) for the financial year | 2,817,791 | 2,906,338 | |||||
Consolidated comprehensive income statement
(amounts in € units) | 3 months | 3 months | |||||
31 March 2024 | 31 March 2023 | ||||||
Profit /(loss) for the financial year (A) | 2,817,791 | 2,906,338 | |||||
Components that will not be subsequently reclassified to profit/(loss) for | |||||||
the financial year | - | ||||||
Revaluation of net employee benefit liabilities/assets | - | ||||||
Tax effect | - | - | |||||
Other comprehensive income (B) components | - | - | |||||
Comprehensive profit/(loss) (A+B) | 2,817,791 | 2,906,338 | |||||
Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 info@finefoods.it
CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02
FINEFOODS.IT
Consolidated statement of financial position
As of 31 | As of 31 | |
March | December | |
(amounts in € units) | 2024 | 2023 |
Assets | ||
Non-current assets | ||
Property, plant and machinery | 108,684,299 | 106,919,123 |
Goodwill | 11,507,954 | 11,507,954 |
Other intangible fixed assets | 1,676,951 | 1,634,888 |
Rights of use | 3,088,138 | 3,165,607 |
Other non-current assets | 626,614 | 688,139 |
Deferred tax assets | 5,496,079 | 6,234,232 |
Total non-current assets | 131,080,036 | 130,149,943 |
Current assets | ||
Inventories | 40,004,751 | 42,459,682 |
Trade receivables | 43,903,752 | 38,057,766 |
Tax receivables | 17,967 | 320,689 |
Other current assets | 8,634,167 | 7,740,856 |
Current financial assets | 3,466,976 | 3,832,865 |
Cash and other liquid assets | 13,888,641 | 19,000,047 |
Total current assets | 109,916,253 | 111,411,905 |
Total assets | 240,996,289 | 241,561,848 |
Shareholders' equity | ||
Share Capital | 22,770,445 | 22,770,445 |
Other reserves | 114,048,701 | 114,167,028 |
Employee benefit reserve | 181,073 | 181,073 |
FTA reserve | (6,669,789) | (6,669,789) |
Profit/(loss) carried forward | (3,499,489) | 22,610 |
Profit/(loss) for the financial year | 2,817,791 | (3,522,098) |
Total Shareholders' Equity | 129,648,732 | 126,949,268 |
Non-current liabilities | ||
Non-current bank borrowings | 41,324,409 | 9,734,877 |
Employee benefits | 2,208,636 | 2,201,653 |
Provision for risks and charges | 2,105 | 2,105 |
Provision for deferred taxes | 273,475 | 263,381 |
Non-current lease payables | 957,221 | 1,032,604 |
Total non-current liabilities | 44,765,846 | 13,234,620 |
Current liabilities | ||
Current bank borrowings | 18,309,960 | 55,269,592 |
Trade payables | 33,200,566 | 32,369,462 |
Taxes payable | 1,010,761 | 575,488 |
Current lease payables | 332,581 | 354,377 |
Other current liabilities | 13,727,843 | 12,809,041 |
Total current liabilities | 66,581,711 | 101,377,960 |
Total Shareholders' equity and Liabilities | 240,996,289 | 241,561,848 |
Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 info@finefoods.it
CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02
FINEFOODS.IT
Consolidated cash flow statement
3 months | 3 months | |
31 March 2024 | 31 March 2023 | |
PROFIT FROM OPERATING ACTIVITIES AFTER TAX | 2,817,791 | 2,906,338 |
Adjustments to reconcile profit after tax with net cash flows: | ||
Depreciation and impairment of property, plant and machinery | 3,483,403 | 3,357,350 |
Amortisation and impairment of intangible fixed assets | 196,420 | 196,564 |
Amortisation of rights of use | 116,283 | 194,588 |
Financial income | 107,537 | (20,086) |
Financial charges | 954,028 | 1,036,765 |
Changes in fair value of financial assets and liabilities | 19,496 | (1,101,887) |
Financial charges on financial liabilities for leases | 13,141 | 17,257 |
Income taxes | 408,250 | 1,322,783 |
Gains on the disposal of property, plant and machinery | (23,926) | 15,709 |
Current assets write-downs | 304,524 | 238,825 |
Net change in severance indemnity and pension funds | 6,982 | (122,835) |
Net change in deferred tax assets and liabilities | 748,246 | 39,010 |
Interest paid | (1,074,706) | (1,021,690) |
Changes in net working capital: | ||
(Increase)/decrease in inventories | 2,398,005 | (8,951,249) |
(Increase)/decrease in trade receivables | (6,093,584) | (12,438,848) |
(Increase)/decrease in other non-financial assets and liabilities | 416,762 | 1,637,920 |
Increase/(decrease) in trade payables | 831,104 | 8,552,478 |
NET CASH FLOWS FROM OPERATING ACTIVITIES | 5,629,756 | (4,141,009) |
Investments: | ||
Investments in tangible fixed assets | (5,304,285) | (4,586,163) |
Disposal of tangible fixed assets | 79,632 | 5,369 |
Investments in intangible fixed assets | (238,482) | (256,346) |
Net (investments)/disposals in financial assets | 195,783 | (1,859,409) |
NET CASH FLOWS FROM INVESTMENTS | 5,267,351 | (6,696,550) |
Financing: | ||
New financing | 162,734 | 15,348,796 |
Funding repayment | (5,382,224) | (12,499,411) |
Principal payments - lease liabilities | (135,992) | (163,056) |
Sale/(purchase) of treasury shares | (118,327) | (87,963) |
CASH FLOWS FROM FINANCING | (5,473,809) | 2,598,366 |
NET CHANGE IN CASH AND CASH EQUIVALENTS | (5,111,405) | (8,239,193) |
Cash and short-term deposits as of 1 January | 19,000,047 | 10,232,262 |
Cash and short-term deposits as of 31 March | 13,888,641 | 1,993,070 |
Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 info@finefoods.it
CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02
FINEFOODS.IT
Consolidated Shareholders' equity changes
Negative | Employ | Profit/loss | |||||||||||||||||||||||||||
reserve for | Merger | Share | Extraordi | Profits/loss | Total | ||||||||||||||||||||||||
Share | Legal | Other | ee | for the | |||||||||||||||||||||||||
treasury | surplus | premium | nary | FTA reserve | es carried | Shareholders | |||||||||||||||||||||||
Capital | reserve | reserves | benefit | financial | |||||||||||||||||||||||||
shares in the | reserve | reserve | reserve | forward | ' equity | ||||||||||||||||||||||||
reserve | year | ||||||||||||||||||||||||||||
portfolio | |||||||||||||||||||||||||||||
Balance as of 1 January | 22,770,445 | 5,000,000 | (14,021,029) | 29,741,389 | 86,743,750 | 2,286,638 | 4,416,281 | (6,669,789) | 181,073 | 22,610 | (3,522,098) | 126,949,268 | |||||||||||||||||
2024 | |||||||||||||||||||||||||||||
Profit/(loss) for the financial | 2,817,791 | 2,817,791 | |||||||||||||||||||||||||||
year | |||||||||||||||||||||||||||||
Other income statement | |||||||||||||||||||||||||||||
components | |||||||||||||||||||||||||||||
Comprehensive profit/(loss) | - | - | - | - | - | - | - | - | - | - | 2,817,791 | 2,817,791 | |||||||||||||||||
Dividends | - | ||||||||||||||||||||||||||||
IRS derivatives provision | - | ||||||||||||||||||||||||||||
Purchase of treasury shares | (118,327) | (118,327) | |||||||||||||||||||||||||||
2023 profit allocation | (3,522,098) | 3,522,098 | - | ||||||||||||||||||||||||||
Balance as of 31 March | 22,770,445 | 5,000,000 | (14,139,356) | 29,741,389 | 86,743,750 | 2,286,638 | 4,416,281 | (6,669,789) | 181,073 | (3,499,488) | 2,817,791 | 129,648,733 | |||||||||||||||||
2024 | |||||||||||||||||||||||||||||
Fine Foods & Pharmaceuticals N.T.M. S.p.A.
Via Berlino, 39 Zingonia-Verdellino 24040 (BG) Italia T. +39 035 4821382 info@finefoods.it
CF / P.IVA IT 09320600969 CAP. SOC. € 22.770.445,02
FINEFOODS.IT
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Fine Foods & Pharmaceuticals NTM S.p.A. published this content on 15 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 May 2024 11:57:59 UTC.